SSY Group Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de SSY Group de 5.8% y 9.7% por año respectivamente. Se prevé que el BPA crezca en un 6% al año. Se espera que la rentabilidad financiera sea de 17.3% en 3 años.

Información clave

5.8%

Tasa de crecimiento de los beneficios

6.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	10.8%
Tasa de crecimiento de los ingresos	9.7%
Rentabilidad financiera futura	17.3%
Cobertura de analistas	Low
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

Previsiones de crecimiento de beneficios e ingresos

SEHK:2005 - Estimaciones futuras de los analistas y datos financieros pasados (HKD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	8,148	1,526	1,218	1,684	4
12/31/2025	7,419	1,421	1,228	1,570	5
12/31/2024	6,615	1,262	788	1,391	5
6/30/2024	6,469	1,366	205	785	N/A
3/31/2024	6,466	1,342	259	855	N/A
12/31/2023	6,463	1,319	313	926	N/A
9/30/2023	6,413	1,255	406	965	N/A
6/30/2023	6,363	1,191	499	1,004	N/A
3/31/2023	6,398	1,157	407	869	N/A
12/31/2022	6,434	1,123	316	734	N/A
9/30/2022	6,376	1,101	318	752	N/A
6/30/2022	6,318	1,080	321	769	N/A
3/31/2022	5,838	933	314	733	N/A
12/31/2021	5,357	786	307	696	N/A
9/30/2021	5,139	713	205	605	N/A
6/30/2021	4,921	641	102	514	N/A
3/31/2021	4,591	626	143	509	N/A
12/31/2020	4,261	612	183	505	N/A
9/30/2020	4,177	723	140	558	N/A
6/30/2020	4,093	835	97	611	N/A
3/31/2020	4,364	985	-47	628	N/A
12/31/2019	4,636	1,136	-190	646	N/A
9/30/2019	4,525	1,075	-164	629	N/A
6/30/2019	4,414	1,014	-138	612	N/A
3/31/2019	4,297	963	126	791	N/A
12/31/2018	4,181	912	390	970	N/A
9/30/2018	4,012	867	385	906	N/A
6/30/2018	3,844	822	380	843	N/A
3/31/2018	3,460	743	N/A	698	N/A
12/31/2017	3,076	665	N/A	552	N/A
9/30/2017	2,827	616	N/A	676	N/A
6/30/2017	2,577	567	N/A	799	N/A
3/31/2017	2,469	528	N/A	743	N/A
12/31/2016	2,361	490	N/A	686	N/A
9/30/2016	2,315	426	N/A	579	N/A
6/30/2016	2,270	363	N/A	472	N/A
3/31/2016	2,246	383	N/A	517	N/A
12/31/2015	2,222	403	N/A	563	N/A
9/30/2015	2,189	443	N/A	326	N/A
6/30/2015	2,156	482	N/A	89	N/A
3/31/2015	2,124	487	N/A	198	N/A
12/31/2014	2,091	492	N/A	308	N/A
6/30/2014	1,309	402	N/A	613	N/A
3/31/2014	1,516	386	N/A	605	N/A
12/31/2013	1,723	369	N/A	598	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (5.8% al año) de 2005 es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (5.8% al año) de 2005 crezcan menos que el mercado Hong Kong (11.6% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 2005 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (9.7% al año) de 2005 crezcan más rápidamente que los del mercado Hong Kong (7.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.7% al año) de 2005 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 2005 sea baja dentro de 3 años (17.3%).

SSY Group Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 14% to HK$6.38

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Price target decreased by 7.7% to HK$6.09

Recent updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China